Working… Menu

Sleep Architecture and Chemotherapy-Related Fatigue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00178204
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : December 5, 2014
American Cancer Society, Inc.
Information provided by (Responsible Party):
Joseph Roscoe, University of Rochester

Brief Summary:

The purpose of this study is to identify specific chemotherapy-related changes in sleep stages/architecture that may relate to an increase in fatigue in individuals with cancer.

The researchers hypothesize that the fatigue experienced by cancer patients receiving chemotherapy is in part due to changes in restorative sleeping during the non-rapid eye movement cycles of sleep (i.e., delta activity).

Condition or disease
Fatigue Sleep Cancer

Detailed Description:

Studies have shown a strong positive correlation between self-reported changes in sleep and cancer patients' fatigue, and also between an objective measure of sleep continuity, [i.e., actigraphy and polysomnography (PSG)] and self-reported fatigue. Chemotherapy disrupts normal sleep patterns, and fatigue, in the later stages of chemotherapy, may occur as a result of disturbed nocturnal sleep continuity. However, the causes of chemotherapy-related fatigue remain unknown, and whether or not abnormal sleep architecture contributes to this debilitating effect has yet to be explored. We believe that fatigue experienced by many cancer patients receiving chemotherapy is due, at least in part, to changes in delta activity [i.e., restorative sleep during the non-rapid eye movement (NREM) cycles of sleep]. A finding that slow wave sleep abnormalities play a significant role in fatigue would prompt further confirmatory studies and support controlled intervention studies.

Comparisons: In a clinical trial of individuals with cancer prior to, during, and after completion of chemotherapy, we will identify and compare specific chemotherapy-related changes in sleep stages/architecture that may relate to an increase in fatigue. These changes will be measured by actigraphy, PSG, and patient self-reporting techniques (e.g., sleep diaries, questionnaires).

The primary objective is to:

  • examine the role of delta sleep in the development of chemotherapy-induced fatigue in cancer patients

Secondary objectives are to:

  • characterize the involvement of other elements of sleep architecture [e.g., rapid eye movement (REM) sleep] and changes in sleep continuity relating to the development of chemotherapy-induced fatigue in cancer patients
  • examine the role of sleep architecture in the persistence of chemotherapy-induced fatigue
  • examine (in post hoc analyses) the relationship of various physical symptoms and patient variables that may be related to fatigue (e.g., pain, hot flashes, anxiety, hemoglobin, menopausal status, sleep continuity, and QOL) and to each other, both during and following chemotherapy.

Answers to these questions will provide information that will be helpful in developing potential targets for interventions to reduce fatigue.

Layout table for study information
Study Type : Observational
Actual Enrollment : 26 participants
Time Perspective: Prospective
Official Title: Sleep Architecture and Chemotherapy-Related Fatigue
Study Start Date : November 2004
Actual Primary Completion Date : May 2009
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue

Primary Outcome Measures :
  1. Polysomnography (PSG) [ Time Frame: Two consecutive nights prior to first chemotherapy, approximately three weeks following the patient's last chemotherapy, and three months following the last treatment. ]
    Polysomnography provides direct and quantitative measures of cortical activity during sleep (in the form of brain waves). The sleep continuity data derived from this technique include sleep latency (time taken to fall asleep), wake after sleep onset time, total sleep time, and sleep efficiency (SE). The sleep architecture information derived from this technique consists of the assessment of sleep in terms of its constituent component stages (i.e., percent Stage-1, Stage-2, SWS, and REM sleep).

Secondary Outcome Measures :
  1. Brief Fatigue Inventory (BFI) [ Time Frame: On the first night of each of the three polysomnography assessments ]
    The Brief Fatigue Inventory is a 9-item, patient-report instrument with established reliability and validity that allows for the rapid assessment of fatigue level in cancer patients. Possible scores on this scale range from 0 - 10 with higher numbers indicating greater fatigue.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients beginning chemotherapy

Inclusion Criteria:

  • Have a diagnosis of cancer and not have had chemotherapy during the prior three years
  • Be scheduled for chemotherapy that is expected to last at least 9 weeks but not more than 33 weeks without concurrent interferon treatment. Radiation therapy is allowed provided it is concluded within the 33 week time period
  • Have a stable sleep/wake schedule (no shift work) with a preferred sleep phase between 10:00 PM and 9:00 AM
  • Be 18 years of age or older
  • Give informed consent
  • If on beta blockers or being treated for depression or a thyroid disorder, the medication has been stable for 3 months

Exclusion Criteria:

  • On a short term basis (less than 3 months), taking any prescription medication for the control of anxiety, sleep, depression, or fatigue OR taking any over-the-counter medications known to affect sleep
  • Diagnosed with post-traumatic stress disorder (PTSD) or have a substance abuse disorder or psychotic disorder (currently or by history)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00178204

Layout table for location information
United States, New York
University of Rochester James P. Wilmot Cancer Center
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
American Cancer Society, Inc.
Layout table for investigator information
Principal Investigator: Joesph A Roscoe, Ph.D. University of Rochester
Layout table for additonal information
Responsible Party: Joseph Roscoe, Research Associate Professor, University of Rochester Identifier: NCT00178204    
Other Study ID Numbers: MRSG-04-233-01-CPPB
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: December 5, 2014
Last Verified: December 2014
Keywords provided by Joseph Roscoe, University of Rochester:
delta sleep
Cancer-related fatigue
Sleep Disturbance
Additional relevant MeSH terms:
Layout table for MeSH terms